BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211214T183000
DTEND;TZID=America/Vancouver:20211214T193000
DTSTAMP:20260515T082733
CREATED:20211119T210005Z
LAST-MODIFIED:20211119T210017Z
UID:17579-1639506600-1639510200@scienceinboston.com
SUMMARY:Koch Institute Directors Panel
DESCRIPTION:Celebrate the enduring legacy of cancer research at MIT. Current and former directors reflect on the past five decades of progress—from seminal discoveries in molecular biology and immunology to new innovations in nanotechnology and precision medicine—and look ahead to future advancements in the fight against cancer. Join in the conversation as we commemorate the people\, projects\, and promise of integrative cancer research. \nFeaturing \nPhillip Sharp\, PhD\nDirector: 1985–1991\nInstitute Professor and Professor of Biology \nRichard Hynes\, PhD\nDirector: 1991–2001\nDaniel K. Ludwig Professor for Cancer Research \nTyler Jacks\, PhD\nDirector: 2001–2021\nDavid H. Koch (1962) Professor of Biology and Daniel K. Ludwig Scholar \nMatthew Vander Heiden\, MD\, PhD\nDirector: 2021–present\nLester Wolfe (1919) Professor of Molecular Biology and Professor of Biology \nModerated by Susan Hockfield\, PhD\nMIT President Emerita and Professor of Neuroscience
URL:https://scienceinboston.com/event/koch-institute-directors-panel/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211214T183000
DTEND;TZID=America/Vancouver:20211214T193000
DTSTAMP:20260515T082733
CREATED:20211119T210005Z
LAST-MODIFIED:20211119T210005Z
UID:27776-1639506600-1639510200@scienceinboston.com
SUMMARY:Koch Institute Directors Panel
DESCRIPTION:Celebrate the enduring legacy of cancer research at MIT. Current and former directors reflect on the past five decades of progress—from seminal discoveries in molecular biology and immunology to new innovations in nanotechnology and precision medicine—and look ahead to future advancements in the fight against cancer. Join in the conversation as we commemorate the people\, projects\, and promise of integrative cancer research. \nFeaturing \nPhillip Sharp\, PhD\nDirector: 1985–1991\nInstitute Professor and Professor of Biology \nRichard Hynes\, PhD\nDirector: 1991–2001\nDaniel K. Ludwig Professor for Cancer Research \nTyler Jacks\, PhD\nDirector: 2001–2021\nDavid H. Koch (1962) Professor of Biology and Daniel K. Ludwig Scholar \nMatthew Vander Heiden\, MD\, PhD\nDirector: 2021–present\nLester Wolfe (1919) Professor of Molecular Biology and Professor of Biology \nModerated by Susan Hockfield\, PhD\nMIT President Emerita and Professor of Neuroscience
URL:https://scienceinboston.com/event/koch-institute-directors-panel-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211212T130000
DTEND;TZID=America/Toronto:20211212T140000
DTSTAMP:20260515T082733
CREATED:20211203T210856Z
LAST-MODIFIED:20211203T210856Z
UID:17817-1639314000-1639317600@scienceinboston.com
SUMMARY:The Science of Making and Saving Memories
DESCRIPTION:Please join us on Sunday\, December 12 at 1pm EST for a conversation between neuroscientists Li-Huei Tsai\, Steve Ramirez ‘15\, and science journalist Lauren Aguirre ‘86. They will explore recent advances in the science of memory and the opportunities and barriers on the road from breakthroughs in the lab to treatments for memory disorders. \n\nAbout the Speakers \n\nProfessor Tsai is the director of MIT’s Picower Institute for Learning and Memory. Her lab applies a multi-disciplinary approach to illuminating the mechanisms behind neurological disorders such as Alzheimer’s. She is also co-founder of Cognito Therapeutics\, a Cambridge-based company with a device in clinical trials that uses gamma brain wave entrainment to improve memory in Alzheimer’s patients. \n\nProfessor Ramirez of Boston University’s Center for Memory and Brain Center for Systems Neuroscience uses optogenetics to manipulate memories in mice. He hopes this fundamental science will elucidate how memories are shaped and suggest new strategies to treat memory and mental health disorders. \n\nLauren Aguirre\, a science journalist who joined the PBS series NOVA during her senior year at MIT\, has produced documentaries\, short-form video series\, podcasts\, and games. Aguirre’s articles on memory and addiction have appeared in STAT\, The Boston Globe\, Undark\, The Scientist\, and PBS. She left NOVA in 2017 to write The Memory Thief.
URL:https://scienceinboston.com/event/the-science-of-making-and-saving-memories/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211212T130000
DTEND;TZID=America/Toronto:20211212T140000
DTSTAMP:20260515T082733
CREATED:20211203T210856Z
LAST-MODIFIED:20211203T210856Z
UID:27779-1639314000-1639317600@scienceinboston.com
SUMMARY:The Science of Making and Saving Memories
DESCRIPTION:Please join us on Sunday\, December 12 at 1pm EST for a conversation between neuroscientists Li-Huei Tsai\, Steve Ramirez ‘15\, and science journalist Lauren Aguirre ‘86. They will explore recent advances in the science of memory and the opportunities and barriers on the road from breakthroughs in the lab to treatments for memory disorders. \n\nAbout the Speakers \n\nProfessor Tsai is the director of MIT’s Picower Institute for Learning and Memory. Her lab applies a multi-disciplinary approach to illuminating the mechanisms behind neurological disorders such as Alzheimer’s. She is also co-founder of Cognito Therapeutics\, a Cambridge-based company with a device in clinical trials that uses gamma brain wave entrainment to improve memory in Alzheimer’s patients. \n\nProfessor Ramirez of Boston University’s Center for Memory and Brain Center for Systems Neuroscience uses optogenetics to manipulate memories in mice. He hopes this fundamental science will elucidate how memories are shaped and suggest new strategies to treat memory and mental health disorders. \n\nLauren Aguirre\, a science journalist who joined the PBS series NOVA during her senior year at MIT\, has produced documentaries\, short-form video series\, podcasts\, and games. Aguirre’s articles on memory and addiction have appeared in STAT\, The Boston Globe\, Undark\, The Scientist\, and PBS. She left NOVA in 2017 to write The Memory Thief.
URL:https://scienceinboston.com/event/the-science-of-making-and-saving-memories-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211210T123000
DTEND;TZID=America/Toronto:20211210T140000
DTSTAMP:20260515T082733
CREATED:20211022T232018Z
LAST-MODIFIED:20211022T232018Z
UID:17090-1639139400-1639144800@scienceinboston.com
SUMMARY:Gene Drives\, Human Health\, and the Environment
DESCRIPTION:This special consortium combines two monthly event series: Health Policy and Bioethics Consortia & Ethics in Research and Biotechnology Consortia.
URL:https://scienceinboston.com/event/gene-drives-human-health-and-the-environment/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211210T123000
DTEND;TZID=America/Toronto:20211210T140000
DTSTAMP:20260515T082733
CREATED:20211022T232018Z
LAST-MODIFIED:20211022T232018Z
UID:27766-1639139400-1639144800@scienceinboston.com
SUMMARY:Gene Drives\, Human Health\, and the Environment
DESCRIPTION:This special consortium combines two monthly event series: Health Policy and Bioethics Consortia & Ethics in Research and Biotechnology Consortia.
URL:https://scienceinboston.com/event/gene-drives-human-health-and-the-environment-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211209T160000
DTEND;TZID=America/Toronto:20211209T170000
DTSTAMP:20260515T082733
CREATED:20211115T015927Z
LAST-MODIFIED:20211115T015927Z
UID:17482-1639065600-1639069200@scienceinboston.com
SUMMARY:Artificial Intelligence for Pathology
DESCRIPTION:Pathology plays a critical role in the diagnosis of disease and the development and implementation of tissue-based prognostic and predictive biomarkers. In this talk\, Andrew H. Beck will discuss the potential for recent advances in artificial intelligence to significantly advance the accuracy\, reliability\, and predictiveness of pathology with applications to both clinical research and practice. \nSpeaker\nAndrew H. Beck earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University\, where he developed one of the first machine learning–based systems for cancer pathology. He has been certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to cofounding PathAI\, Beck was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology\, cancer pathology\, and biomedical informatics. \nHarvard Radcliffe Institute gratefully acknowledges the following funds that are supporting this event:\nMary E. and Clara Z. Costanza Fund for Science\nMelanie Mason and David W. Niemiec Fund for Science \nRegister\nFree and open to the public. To view this event online\, individuals will need to register via Zoom. \nFor instructions on how to join\, see the How to Attend a Radcliffe Event on Zoom webpage. \nAfter registering\, you will receive a confirmation e-mail containing a link and password for this meeting. \nLive closed captioning will be available for this webinar.
URL:https://scienceinboston.com/event/artificial-intelligence-for-pathology/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211209T160000
DTEND;TZID=America/Toronto:20211209T170000
DTSTAMP:20260515T082733
CREATED:20211115T015927Z
LAST-MODIFIED:20211115T015927Z
UID:27772-1639065600-1639069200@scienceinboston.com
SUMMARY:Artificial Intelligence for Pathology
DESCRIPTION:Pathology plays a critical role in the diagnosis of disease and the development and implementation of tissue-based prognostic and predictive biomarkers. In this talk\, Andrew H. Beck will discuss the potential for recent advances in artificial intelligence to significantly advance the accuracy\, reliability\, and predictiveness of pathology with applications to both clinical research and practice. \nSpeaker\nAndrew H. Beck earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University\, where he developed one of the first machine learning–based systems for cancer pathology. He has been certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to cofounding PathAI\, Beck was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology\, cancer pathology\, and biomedical informatics. \nHarvard Radcliffe Institute gratefully acknowledges the following funds that are supporting this event:\nMary E. and Clara Z. Costanza Fund for Science\nMelanie Mason and David W. Niemiec Fund for Science \nRegister\nFree and open to the public. To view this event online\, individuals will need to register via Zoom. \nFor instructions on how to join\, see the How to Attend a Radcliffe Event on Zoom webpage. \nAfter registering\, you will receive a confirmation e-mail containing a link and password for this meeting. \nLive closed captioning will be available for this webinar.
URL:https://scienceinboston.com/event/artificial-intelligence-for-pathology-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211208T150000
DTEND;TZID=America/Toronto:20211208T160000
DTSTAMP:20260515T082733
CREATED:20211203T232925Z
LAST-MODIFIED:20211203T232925Z
UID:17843-1638975600-1638979200@scienceinboston.com
SUMMARY:The Broken Bridge: Restoring the Connection between Science and the Public
DESCRIPTION:Science — powering our economy and solving our most intractable problems — has never been more central to public life. Yet at the same time\, it remains disconnected from society\, even untrusted. What role do communicators have in restoring this connection? \nJoin us online at 3 PM EST on Wednesday\, December 8th to explore this topic \nModerator: \nMariette DiChristina (COM ’86)\, COM dean; former editor-in-chief and executive vice president\, Scientific American \nPanelists: \nJoe Palca\, NPR science correspondent; founder of SciCommers \nBeth Daley\, editor-in-chief and general manager\, The Conversation US \nMichelle Amazeen\,  director\, Communication Research Center; COM associate professor \nThe webinar will be conducted using the online Zoom webinar platform. Access information and additional instructions on using the Zoom platform will be provided via email upon successful registration. This webinar is open to all members of the BU community including alumni\, students\, faculty\, and staff.
URL:https://scienceinboston.com/event/the-broken-bridge-restoring-the-connection-between-science-and-the-public/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211208T150000
DTEND;TZID=America/Toronto:20211208T160000
DTSTAMP:20260515T082733
CREATED:20211203T232925Z
LAST-MODIFIED:20211203T232925Z
UID:27780-1638975600-1638979200@scienceinboston.com
SUMMARY:The Broken Bridge: Restoring the Connection between Science and the Public
DESCRIPTION:Science — powering our economy and solving our most intractable problems — has never been more central to public life. Yet at the same time\, it remains disconnected from society\, even untrusted. What role do communicators have in restoring this connection? \nJoin us online at 3 PM EST on Wednesday\, December 8th to explore this topic \nModerator: \nMariette DiChristina (COM ’86)\, COM dean; former editor-in-chief and executive vice president\, Scientific American \nPanelists: \nJoe Palca\, NPR science correspondent; founder of SciCommers \nBeth Daley\, editor-in-chief and general manager\, The Conversation US \nMichelle Amazeen\,  director\, Communication Research Center; COM associate professor \nThe webinar will be conducted using the online Zoom webinar platform. Access information and additional instructions on using the Zoom platform will be provided via email upon successful registration. This webinar is open to all members of the BU community including alumni\, students\, faculty\, and staff.
URL:https://scienceinboston.com/event/the-broken-bridge-restoring-the-connection-between-science-and-the-public-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211207T130000
DTEND;TZID=America/Toronto:20211207T140000
DTSTAMP:20260515T082733
CREATED:20211115T021009Z
LAST-MODIFIED:20211115T212541Z
UID:17485-1638882000-1638885600@scienceinboston.com
SUMMARY:Aligning Financial Management Systems to the Biotech Lifecycle: From Pre-Commercial to High Growth
DESCRIPTION:Aligning Financial Management Systems to the Biotech Lifecycle: From Pre-Commercial to High Growth \nLife Science companies have increasingly complex businesses\, and with this comes increasingly complex finances. Dynamic business drivers such as partnerships and alliances\, joint ventures\, and innovative R&D funding frameworks all combine to bring a new level of complexity to operations that directly impacts financial planning\, reporting and compliance. Companies at all stages of the growth lifecycle in life sciences – from pre-commercial to established market contenders – are all seeking ways to mature their financial management processes. In this session featuring KPMG finance professionals\, hear from experts on a range of topics: \n\nA framework designed for pre-commercial companies to enhance financial planning and budgeting\, drawing in aspects of biopharma businesses such as grants\, R&D expenses\, employee costs\, and G&A to produce an Excel-based workbook that supports enhanced reporting\, analysis\, and strategic planning.\nDiscussion of how more mature life sciences companies are using digital technologies – including SAP S/4HANA – to transform the way they integrate operations and financial management to achieve new levels of business efficiency. The discussion will highlight case studies employing a leading practice target operating model designed specifically for high growth life sciences companies.\n\nMassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations\, such as captioning.
URL:https://scienceinboston.com/event/aligning-financial-management-systems-to-the-biotech-lifecycle-from-pre-commercial-to-high-growth/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211207T130000
DTEND;TZID=America/Toronto:20211207T140000
DTSTAMP:20260515T082733
CREATED:20211115T021009Z
LAST-MODIFIED:20211115T021009Z
UID:27773-1638882000-1638885600@scienceinboston.com
SUMMARY:Aligning Financial Management Systems to the Biotech Lifecycle: From Pre-Commercial to High Growth
DESCRIPTION:Aligning Financial Management Systems to the Biotech Lifecycle: From Pre-Commercial to High Growth \nLife Science companies have increasingly complex businesses\, and with this comes increasingly complex finances. Dynamic business drivers such as partnerships and alliances\, joint ventures\, and innovative R&D funding frameworks all combine to bring a new level of complexity to operations that directly impacts financial planning\, reporting and compliance. Companies at all stages of the growth lifecycle in life sciences – from pre-commercial to established market contenders – are all seeking ways to mature their financial management processes. In this session featuring KPMG finance professionals\, hear from experts on a range of topics: \n\nA framework designed for pre-commercial companies to enhance financial planning and budgeting\, drawing in aspects of biopharma businesses such as grants\, R&D expenses\, employee costs\, and G&A to produce an Excel-based workbook that supports enhanced reporting\, analysis\, and strategic planning.\nDiscussion of how more mature life sciences companies are using digital technologies – including SAP S/4HANA – to transform the way they integrate operations and financial management to achieve new levels of business efficiency. The discussion will highlight case studies employing a leading practice target operating model designed specifically for high growth life sciences companies.\n\nMassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations\, such as captioning.
URL:https://scienceinboston.com/event/aligning-financial-management-systems-to-the-biotech-lifecycle-from-pre-commercial-to-high-growth-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211206T150000
DTEND;TZID=America/Toronto:20211206T160000
DTSTAMP:20260515T082733
CREATED:20211119T205744Z
LAST-MODIFIED:20211119T205808Z
UID:17576-1638802800-1638806400@scienceinboston.com
SUMMARY:MIT.nano Seminar: Lipid Nanoparticles for RNA Delivery: SARS-CoV-2 Vaccines\, Chemistry\, and Beyond
DESCRIPTION:Kathryn Whitehead\nAssociate Professor and Dean’s Career Fellow\nChemical Engineering and Biomedical Engineering\nCarnegie Mellon University \nDate: Monday\, December 6\, 2021\nTime: 3:00 PM – 4:00 PM EST\nLocation: Zoom webinar; register to receive the link. \n>>Register.\nABSTRACT \nMessenger RNA (mRNA) therapeutics have been thrust into the limelight\, thanks to the early\, positive clinical trial news on a SARS-CoV2 vaccine from Pfizer/BioNTech and Moderna. These vaccines were made possible by a herculean effort to overcome the most significant barriers that have hindered translational efforts. Arguably\, the largest challenge has been that RNA molecules do not readily enter their cellular targets within the body. This is because they are large (104 – 106 g/mol) and negatively charged; they do not have favorable biodistribution properties nor an ability to cross the cellular membrane of target cells. \nIn response to these issues\, industrial and academic laboratories\, including Whitehead’s\, have created lipid nanoparticles that spontaneously package RNA and deliver the RNA to key cellular targets in vivo. Here\, Whitehead will describe biodegradable\, ionizable lipid-like materials called ‘lipidoids’ that her lab has used to create RNA-loaded lipid nanoparticles that induce protein expression in mice. Lipidoids efficiently manipulate gene expression in a variety of biological systems\, including the liver\, the lungs\, and immune cells. \nThis talk will describe an especially potent lipid nanoparticle\, its chemical characteristics that confer efficacy\, and potential applications. Together\, these data advance our understanding of lipid nanoparticle chemistry and are expected to contribute to the successful formulation of future generations of mRNA therapies. \nBIOGRAPHY \nKathryn A. Whitehead is an associate professor and Dean’s career fellow in the Departments of Chemical Engineering and Biomedical Engineering (courtesy) at Carnegie Mellon University. Her lab develops drug delivery systems for RNA\, proteins\, and for applications in maternal and infant health. \nWhitehead received an H.B.Ch.E Degree with Distinction from the University of Delaware (2002) and a Ph.D. in chemical engineering from the University of California\, Santa Barbara (2007) before an NIH Ruth L. Kirschstein Postdoctoral Fellowship at MIT (2008 – 2012). Whitehead is the recipient of numerous awards\, including the NIH Director’s New Innovator Award\, the DARPA Director’s Fellowship\, and the ASEE Curtis W. McGraw Research Award. She has also received the Controlled Release Society’s Young Investigator Award and served on the society’s Board of Directors. Whitehead is an elected Fellow of the American Institute for Medical and Biological Engineering\, and was named as a Pioneer on the MIT Technology Review’s Innovators Under 35 list and as one of the Brilliant Ten by Popular Science. Her publications have been cited over 7\,000 times\, and several of her patents have been licensed and sublicensed for reagent and therapeutic use.
URL:https://scienceinboston.com/event/mit-nano-seminar-lipid-nanoparticles-for-rna-delivery-sars-cov-2-vaccines-chemistry-and-beyond/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211206T150000
DTEND;TZID=America/Toronto:20211206T160000
DTSTAMP:20260515T082733
CREATED:20211119T205744Z
LAST-MODIFIED:20211119T205744Z
UID:27775-1638802800-1638806400@scienceinboston.com
SUMMARY:MIT.nano Seminar: Lipid Nanoparticles for RNA Delivery: SARS-CoV-2 Vaccines\, Chemistry\, and Beyond
DESCRIPTION:Kathryn Whitehead\nAssociate Professor and Dean’s Career Fellow\nChemical Engineering and Biomedical Engineering\nCarnegie Mellon University \nDate: Monday\, December 6\, 2021\nTime: 3:00 PM – 4:00 PM EST\nLocation: Zoom webinar; register to receive the link. \n>>Register.\nABSTRACT \nMessenger RNA (mRNA) therapeutics have been thrust into the limelight\, thanks to the early\, positive clinical trial news on a SARS-CoV2 vaccine from Pfizer/BioNTech and Moderna. These vaccines were made possible by a herculean effort to overcome the most significant barriers that have hindered translational efforts. Arguably\, the largest challenge has been that RNA molecules do not readily enter their cellular targets within the body. This is because they are large (104 – 106 g/mol) and negatively charged; they do not have favorable biodistribution properties nor an ability to cross the cellular membrane of target cells. \nIn response to these issues\, industrial and academic laboratories\, including Whitehead’s\, have created lipid nanoparticles that spontaneously package RNA and deliver the RNA to key cellular targets in vivo. Here\, Whitehead will describe biodegradable\, ionizable lipid-like materials called ‘lipidoids’ that her lab has used to create RNA-loaded lipid nanoparticles that induce protein expression in mice. Lipidoids efficiently manipulate gene expression in a variety of biological systems\, including the liver\, the lungs\, and immune cells. \nThis talk will describe an especially potent lipid nanoparticle\, its chemical characteristics that confer efficacy\, and potential applications. Together\, these data advance our understanding of lipid nanoparticle chemistry and are expected to contribute to the successful formulation of future generations of mRNA therapies. \nBIOGRAPHY \nKathryn A. Whitehead is an associate professor and Dean’s career fellow in the Departments of Chemical Engineering and Biomedical Engineering (courtesy) at Carnegie Mellon University. Her lab develops drug delivery systems for RNA\, proteins\, and for applications in maternal and infant health. \nWhitehead received an H.B.Ch.E Degree with Distinction from the University of Delaware (2002) and a Ph.D. in chemical engineering from the University of California\, Santa Barbara (2007) before an NIH Ruth L. Kirschstein Postdoctoral Fellowship at MIT (2008 – 2012). Whitehead is the recipient of numerous awards\, including the NIH Director’s New Innovator Award\, the DARPA Director’s Fellowship\, and the ASEE Curtis W. McGraw Research Award. She has also received the Controlled Release Society’s Young Investigator Award and served on the society’s Board of Directors. Whitehead is an elected Fellow of the American Institute for Medical and Biological Engineering\, and was named as a Pioneer on the MIT Technology Review’s Innovators Under 35 list and as one of the Brilliant Ten by Popular Science. Her publications have been cited over 7\,000 times\, and several of her patents have been licensed and sublicensed for reagent and therapeutic use.
URL:https://scienceinboston.com/event/mit-nano-seminar-lipid-nanoparticles-for-rna-delivery-sars-cov-2-vaccines-chemistry-and-beyond-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211130T160000
DTEND;TZID=America/Toronto:20211130T170000
DTSTAMP:20260515T082733
CREATED:20211119T205318Z
LAST-MODIFIED:20211122T195941Z
UID:17573-1638288000-1638291600@scienceinboston.com
SUMMARY:Biology Colloquium Series: Dr. Omer Yilmaz
DESCRIPTION:Speaker: Dr. Omer Yilmaz\, MIT. \nHosted by Alan Grossman \nTitle:  “Dietary control of intestinal stem cells in physiology and disease.” \nThe Biology Colloquium is a weekly seminar held throughout the academic year\, featuring distinguished speakers in many areas of the biological sciences\, from universities and institutions worldwide. More information on speakers\, their affiliations\, and titles of their talks will be added as available. \nThe Colloquium will zoom at 4:00PM  Tuesdays during the fall school year. Contact: Magaret Cabral\, mcabral1@mit.edu
URL:https://scienceinboston.com/event/biology-colloquium-series-dr-omer-yilmaz/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211130T160000
DTEND;TZID=America/Toronto:20211130T170000
DTSTAMP:20260515T082733
CREATED:20211119T205318Z
LAST-MODIFIED:20211119T205318Z
UID:27774-1638288000-1638291600@scienceinboston.com
SUMMARY:Biology Colloquium Series: Dr. Omer Yilmaz
DESCRIPTION:Speaker: Dr. Omer Yilmaz\, MIT. \nHosted by Alan Grossman \nTitle:  “Dietary control of intestinal stem cells in physiology and disease.” \nThe Biology Colloquium is a weekly seminar held throughout the academic year\, featuring distinguished speakers in many areas of the biological sciences\, from universities and institutions worldwide. More information on speakers\, their affiliations\, and titles of their talks will be added as available. \nThe Colloquium will zoom at 4:00PM  Tuesdays during the fall school year. Contact: Magaret Cabral\, mcabral1@mit.edu
URL:https://scienceinboston.com/event/biology-colloquium-series-dr-omer-yilmaz-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211130T160000
DTEND;TZID=America/Toronto:20211130T170000
DTSTAMP:20260515T082733
CREATED:20211115T015614Z
LAST-MODIFIED:20211115T015614Z
UID:17479-1638288000-1638291600@scienceinboston.com
SUMMARY:How Cancer Spreads
DESCRIPTION:For two decades\, we have understood how normal human cells can be converted in cancer cells and form primary tumors. But it has been unclear what mechanisms allow primary tumors to become actively malignant and life-threatening. \nRecently\, though\, insights into cellular programs that operate during embryo formation and wound healing have yielded clues to how primary cancer cells learn to invade nearby tissues and spread throughout the body.\nThis webinar will focus on the next\, challenging question: How do cancer cells arising in one tissue learn to adapt and proliferate in tissues to which they have spread through metastasis?
URL:https://scienceinboston.com/event/how-cancer-spreads/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211130T160000
DTEND;TZID=America/Toronto:20211130T170000
DTSTAMP:20260515T082733
CREATED:20211115T015614Z
LAST-MODIFIED:20211115T015614Z
UID:27771-1638288000-1638291600@scienceinboston.com
SUMMARY:How Cancer Spreads
DESCRIPTION:For two decades\, we have understood how normal human cells can be converted in cancer cells and form primary tumors. But it has been unclear what mechanisms allow primary tumors to become actively malignant and life-threatening. \nRecently\, though\, insights into cellular programs that operate during embryo formation and wound healing have yielded clues to how primary cancer cells learn to invade nearby tissues and spread throughout the body.\nThis webinar will focus on the next\, challenging question: How do cancer cells arising in one tissue learn to adapt and proliferate in tissues to which they have spread through metastasis?
URL:https://scienceinboston.com/event/how-cancer-spreads-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211130T120000
DTEND;TZID=America/Vancouver:20211130T130000
DTSTAMP:20260515T082733
CREATED:20211119T210325Z
LAST-MODIFIED:20211119T210325Z
UID:17582-1638273600-1638277200@scienceinboston.com
SUMMARY:Regulatory Science Forum: New Funding and Business Models for Accelerating Biomedical Innovation
DESCRIPTION:Most experts agree that we are in the midst of a golden age of biomedical innovation. Technologies breakthroughs such as next-generation sequencing\, gene editing\, immunotherapies\, mRNA technology\, and AI-enhanced drug discovery have permanently changed the way we treat diseases. However\, the funding and business models we use to commercialize these technologies are still largely the same\, making it particularly challenging for younger scientists to bring their ideas into practice. In this talk\, Dr. Andrew Lo – Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management – will describe the financial considerations that create bottlenecks in the commercialization process and discuss current and emerging solutions\, including venture philanthropy\, portfolio companies\, and securitization techniques. No finance background is assumed\, but attendees should be prepared to participate in one or two live financial transactions during the seminar.
URL:https://scienceinboston.com/event/regulatory-science-forum-new-funding-and-business-models-for-accelerating-biomedical-innovation/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20211130T120000
DTEND;TZID=America/Vancouver:20211130T130000
DTSTAMP:20260515T082733
CREATED:20211119T210325Z
LAST-MODIFIED:20211119T210325Z
UID:27777-1638273600-1638277200@scienceinboston.com
SUMMARY:Regulatory Science Forum: New Funding and Business Models for Accelerating Biomedical Innovation
DESCRIPTION:Most experts agree that we are in the midst of a golden age of biomedical innovation. Technologies breakthroughs such as next-generation sequencing\, gene editing\, immunotherapies\, mRNA technology\, and AI-enhanced drug discovery have permanently changed the way we treat diseases. However\, the funding and business models we use to commercialize these technologies are still largely the same\, making it particularly challenging for younger scientists to bring their ideas into practice. In this talk\, Dr. Andrew Lo – Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management – will describe the financial considerations that create bottlenecks in the commercialization process and discuss current and emerging solutions\, including venture philanthropy\, portfolio companies\, and securitization techniques. No finance background is assumed\, but attendees should be prepared to participate in one or two live financial transactions during the seminar.
URL:https://scienceinboston.com/event/regulatory-science-forum-new-funding-and-business-models-for-accelerating-biomedical-innovation-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211119T123000
DTEND;TZID=America/Toronto:20211119T140000
DTSTAMP:20260515T082733
CREATED:20211022T230513Z
LAST-MODIFIED:20211022T230513Z
UID:17086-1637325000-1637330400@scienceinboston.com
SUMMARY:What We Can Learn from the ACE2 Cellular Receptor – Past\, Present\, and Future?
DESCRIPTION:This monthly seminar series explores issues at the intersection of ethics\, technology\, and bioscience with an eye toward practical approaches\, policies and ethical responsibilities. \nJoin us online for the November Ethics in Research and Biotechnology Consortium discussing “What We Can Learn from the ACE2 Cellular Receptor – Past\, Present\, and Future?” with Josef Penninger\, MD.
URL:https://scienceinboston.com/event/what-we-can-learn-from-the-ace2-cellular-receptor-past-present-and-future/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211119T123000
DTEND;TZID=America/Toronto:20211119T140000
DTSTAMP:20260515T082733
CREATED:20211022T230513Z
LAST-MODIFIED:20211022T230513Z
UID:27765-1637325000-1637330400@scienceinboston.com
SUMMARY:What We Can Learn from the ACE2 Cellular Receptor – Past\, Present\, and Future?
DESCRIPTION:This monthly seminar series explores issues at the intersection of ethics\, technology\, and bioscience with an eye toward practical approaches\, policies and ethical responsibilities. \nJoin us online for the November Ethics in Research and Biotechnology Consortium discussing “What We Can Learn from the ACE2 Cellular Receptor – Past\, Present\, and Future?” with Josef Penninger\, MD.
URL:https://scienceinboston.com/event/what-we-can-learn-from-the-ace2-cellular-receptor-past-present-and-future-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211117T170000
DTEND;TZID=America/Toronto:20211117T180000
DTSTAMP:20260515T082733
CREATED:20211022T225956Z
LAST-MODIFIED:20211022T230241Z
UID:17083-1637168400-1637172000@scienceinboston.com
SUMMARY:Biomedical Informatics Entrepreneurs Salon: Najat Khan\, Janssen R&D
DESCRIPTION:BIES is a monthly conversation about medicine\, biology\, computers\, and entrepreneurship. \nFeatured Speaker \nNajat S. Khan\, PhD\, is Chief Data Science Officer for Janssen R&D Data Sciences\, and Global Head of Janssen R&D Strategy and Operations. \nAs Chief Data Science Officer at Janssen Research & Development\, Najat is responsible for identifying and executing high-impact initiatives across Discovery and Development\, including by curating external partnerships that enrich data availability and enable rapid deployment and scale. These data science efforts span Janssen’s portfolio\, including a key role in COVID-19 vaccine development. Najat also serves as Global Head of Janssen R&D Strategy & Operations and co-leads the cross-sector J&J Data Science Council. Najat received her B.A. in Chemistry from Colgate University and her Ph.D. in Organic Chemistry from the University of Pennsylvania.
URL:https://scienceinboston.com/event/biomedical-informatics-entrepreneurs-salon-najat-khan-janssen-rd-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211117T170000
DTEND;TZID=America/Toronto:20211117T180000
DTSTAMP:20260515T082733
CREATED:20211022T225956Z
LAST-MODIFIED:20211022T225956Z
UID:27764-1637168400-1637172000@scienceinboston.com
SUMMARY:Biomedical Informatics Entrepreneurs Salon: Najat Khan\, Janssen R&D
DESCRIPTION:BIES is a monthly conversation about medicine\, biology\, computers\, and entrepreneurship. \nFeatured Speaker \nNajat S. Khan\, PhD\, is Chief Data Science Officer for Janssen R&D Data Sciences\, and Global Head of Janssen R&D Strategy and Operations. \nAs Chief Data Science Officer at Janssen Research & Development\, Najat is responsible for identifying and executing high-impact initiatives across Discovery and Development\, including by curating external partnerships that enrich data availability and enable rapid deployment and scale. These data science efforts span Janssen’s portfolio\, including a key role in COVID-19 vaccine development. Najat also serves as Global Head of Janssen R&D Strategy & Operations and co-leads the cross-sector J&J Data Science Council. Najat received her B.A. in Chemistry from Colgate University and her Ph.D. in Organic Chemistry from the University of Pennsylvania.
URL:https://scienceinboston.com/event/biomedical-informatics-entrepreneurs-salon-najat-khan-janssen-rd-2-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211116T190000
DTEND;TZID=America/Toronto:20211116T200000
DTSTAMP:20260515T082733
CREATED:20211103T194858Z
LAST-MODIFIED:20211103T194858Z
UID:17258-1637089200-1637092800@scienceinboston.com
SUMMARY:How Fundamental Science Becomes Treatment at Boston Children's Hospital: A Conversation with Kevin Churchwell
DESCRIPTION:You are invited to join Ruth Lehmann\, President and Director of the Whitehead Institute\, for a series of virtual dialogues with scientific luminaries from academia\, and visionary leaders from the biotech industry. \nWhat trends in science and technology excite them the most? Which innovations have the potential to dramatically impact the way we live and work? \nBe a part of the conversation. \nKevin B. Churchwell\, MD\, is the President and Chief Executive Officer of Boston Children’s Hospital\, providing leadership\, vision\, and oversight for a team that’s dedicated to improving and advancing child health through their life-changing work in clinical care\, research and innovation\, medical education\, and community engagement. \nSince joining Boston Children’s as its Executive Vice President of Health Affairs Chief Operating Officer in 2013\, Dr. Churchwell has been instrumental in leading the hospital’s work to become a High Reliability Organization\, one where zero avoidable harm impacts any patient\, family member\, or employee. He has brought to Boston the same passion for enhancing the patient family experience that defined his tenure as CEO of both Nemours/Alfred I. duPont Hospital for Children in Wilmington\, DE\, and Monroe Carell Jr. Children’s Hospital\, part of the Vanderbilt University Medical Center in Nashville\, TN. \nAn advocate for equity\, diversity and inclusivity\, Dr. Churchwell is responsible for establishing three of the 11 Offices of Health Equity and Inclusion at hospitals across the U.S. and Canada\, including the Office at Boston Children’s\, which he founded in 2016. With the publication of Boston Children’s own Declaration for Equity\, Diversity and Inclusivity in 2020\, Dr. Churchwell has committed to the work required to make Boston Children’s a community that’s made stronger by our differences\, and a leader in equity for all. \nA graduate of Massachusetts Institute of Technology and Vanderbilt Medical School in Nashville\, Dr. Churchwell completed his pediatric residency and a clinical fellowship in Pediatric Critical Care at Boston Children’s Hospital. He is currently an Associate Professor of Pediatric Anesthesia at Harvard Medical School and Dr. Churchwell is the Robert and Dana Smith Associate Professor of Anesthesia at the Harvard Medical School.
URL:https://scienceinboston.com/event/how-fundamental-science-becomes-treatment-at-boston-childrens-hospital-a-conversation-with-kevin-churchwell/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211116T190000
DTEND;TZID=America/Toronto:20211116T200000
DTSTAMP:20260515T082733
CREATED:20211103T194858Z
LAST-MODIFIED:20211103T194858Z
UID:27770-1637089200-1637092800@scienceinboston.com
SUMMARY:How Fundamental Science Becomes Treatment at Boston Children's Hospital: A Conversation with Kevin Churchwell
DESCRIPTION:You are invited to join Ruth Lehmann\, President and Director of the Whitehead Institute\, for a series of virtual dialogues with scientific luminaries from academia\, and visionary leaders from the biotech industry. \nWhat trends in science and technology excite them the most? Which innovations have the potential to dramatically impact the way we live and work? \nBe a part of the conversation. \nKevin B. Churchwell\, MD\, is the President and Chief Executive Officer of Boston Children’s Hospital\, providing leadership\, vision\, and oversight for a team that’s dedicated to improving and advancing child health through their life-changing work in clinical care\, research and innovation\, medical education\, and community engagement. \nSince joining Boston Children’s as its Executive Vice President of Health Affairs Chief Operating Officer in 2013\, Dr. Churchwell has been instrumental in leading the hospital’s work to become a High Reliability Organization\, one where zero avoidable harm impacts any patient\, family member\, or employee. He has brought to Boston the same passion for enhancing the patient family experience that defined his tenure as CEO of both Nemours/Alfred I. duPont Hospital for Children in Wilmington\, DE\, and Monroe Carell Jr. Children’s Hospital\, part of the Vanderbilt University Medical Center in Nashville\, TN. \nAn advocate for equity\, diversity and inclusivity\, Dr. Churchwell is responsible for establishing three of the 11 Offices of Health Equity and Inclusion at hospitals across the U.S. and Canada\, including the Office at Boston Children’s\, which he founded in 2016. With the publication of Boston Children’s own Declaration for Equity\, Diversity and Inclusivity in 2020\, Dr. Churchwell has committed to the work required to make Boston Children’s a community that’s made stronger by our differences\, and a leader in equity for all. \nA graduate of Massachusetts Institute of Technology and Vanderbilt Medical School in Nashville\, Dr. Churchwell completed his pediatric residency and a clinical fellowship in Pediatric Critical Care at Boston Children’s Hospital. He is currently an Associate Professor of Pediatric Anesthesia at Harvard Medical School and Dr. Churchwell is the Robert and Dana Smith Associate Professor of Anesthesia at the Harvard Medical School.
URL:https://scienceinboston.com/event/how-fundamental-science-becomes-treatment-at-boston-childrens-hospital-a-conversation-with-kevin-churchwell-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211113T180000
DTEND;TZID=America/Toronto:20211113T210000
DTSTAMP:20260515T082733
CREATED:20211022T215018Z
LAST-MODIFIED:20211022T215018Z
UID:17061-1636826400-1636837200@scienceinboston.com
SUMMARY:High Hopes Gala
DESCRIPTION:In celebration of the 100th anniversary of the discovery of insulin\, we are proud to honor the top 100 individuals\, advancements\, groups\, corporations and foundations that we\, at Joslin\, admire and appreciate for their impact on the diabetes community over the last century. We are grateful for their innovation\, imagination and advocacy that has allowed for new discoveries in the journey to find a cure. \nThis year’s Gala will take place as a live broadcast from our studio location. Our guests will have the unique opportunity to view the event as it unfolds from the comfort and safety of their own homes. You won’t want to miss this! \nThis distinctive event raises funds for Joslin’s High Hopes Fund\, which directly supports Joslin’s most important efforts to identify breakthrough advancements in diabetes research and clinical care. The High Hopes Fund provides immediate support of our most critical needs- whether that’s funding a promising new research project\, educating a patient on new technology or supporting patient care that seamlessly address all areas of a complex disease. \nWe hope you will join us in celebration of Joslin’s mission so we don’t have to wait another 100 years for a cure.
URL:https://scienceinboston.com/event/high-hopes-gala/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211113T180000
DTEND;TZID=America/Toronto:20211113T210000
DTSTAMP:20260515T082733
CREATED:20211022T215018Z
LAST-MODIFIED:20211022T215018Z
UID:27758-1636826400-1636837200@scienceinboston.com
SUMMARY:High Hopes Gala
DESCRIPTION:In celebration of the 100th anniversary of the discovery of insulin\, we are proud to honor the top 100 individuals\, advancements\, groups\, corporations and foundations that we\, at Joslin\, admire and appreciate for their impact on the diabetes community over the last century. We are grateful for their innovation\, imagination and advocacy that has allowed for new discoveries in the journey to find a cure. \nThis year’s Gala will take place as a live broadcast from our studio location. Our guests will have the unique opportunity to view the event as it unfolds from the comfort and safety of their own homes. You won’t want to miss this! \nThis distinctive event raises funds for Joslin’s High Hopes Fund\, which directly supports Joslin’s most important efforts to identify breakthrough advancements in diabetes research and clinical care. The High Hopes Fund provides immediate support of our most critical needs- whether that’s funding a promising new research project\, educating a patient on new technology or supporting patient care that seamlessly address all areas of a complex disease. \nWe hope you will join us in celebration of Joslin’s mission so we don’t have to wait another 100 years for a cure.
URL:https://scienceinboston.com/event/high-hopes-gala-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211110T160000
DTEND;TZID=America/Toronto:20211110T164500
DTSTAMP:20260515T082733
CREATED:20211029T162610Z
LAST-MODIFIED:20211029T162610Z
UID:17190-1636560000-1636562700@scienceinboston.com
SUMMARY:STEMCELL Cambridge Career Open House
DESCRIPTION:Join our virtual career open house to learn more about becoming a Scientific Sales or Scientific Support Representative at STEMCELL Technologies. We’re looking for enthusiastic and science-oriented people to join our team based in Cambridge\, MA. \n\n\n\nTime: Wednesday\, November 10\, 2021\, 4:00 – 4:45 p.m.\n\nLocation: Zoom Meeting – A virtual meeting invite will be sent to you
URL:https://scienceinboston.com/event/stemcell-cambridge-career-open-house/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2021/10/CR385-Virtual-Open-House-Cambridge-form.jpg
ORGANIZER;CN="STEMCELL Technologies":MAILTO:info@stemcell.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20211110T160000
DTEND;TZID=America/Toronto:20211110T164500
DTSTAMP:20260515T082733
CREATED:20211029T162610Z
LAST-MODIFIED:20211029T162610Z
UID:27768-1636560000-1636562700@scienceinboston.com
SUMMARY:STEMCELL Cambridge Career Open House
DESCRIPTION:Join our virtual career open house to learn more about becoming a Scientific Sales or Scientific Support Representative at STEMCELL Technologies. We’re looking for enthusiastic and science-oriented people to join our team based in Cambridge\, MA. \n\n\n\nTime: Wednesday\, November 10\, 2021\, 4:00 – 4:45 p.m.\n\nLocation: Zoom Meeting – A virtual meeting invite will be sent to you
URL:https://scienceinboston.com/event/stemcell-cambridge-career-open-house-2/
LOCATION:Online
ATTACH;FMTTYPE=image/jpeg:https://scienceinboston.com/wp-content/uploads/sites/6/2021/10/CR385-Virtual-Open-House-Cambridge-form.jpg
ORGANIZER;CN="STEMCELL Technologies":MAILTO:info@stemcell.com
END:VEVENT
END:VCALENDAR